Granted Patent
B2
US 12,527,808 · App. 17/638,332 · Granted Jan 20, 2026
Compounds useful to treat pain
Inventors:
Pathik Subhashchandra Brahmkshatriya (Ahmedabad, IN); Vishal Bharatbhai Unadkat (Ahmedabad, IN); Vishalgiri Gunvantgiri Goswami (Ahmedabad, IN); Heta Nishil Pandya (Ahmedabad, IN); Sandip Pareshbhai Mehta (Ahmedabad, IN)
Assignee:
AMNEAL PHARMACEUTICALS LLC
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to compounds useful as bradykinin receptor antagonist, pharmaceutical composition comprising such compounds, and therapeutic use of the same. The present invention further relates to the combination of compounds useful for the therapeutic use. The present invention relates to the pharmaceutical composition comprising the compound and combination of compounds useful for treatment of urinary bladder pain, the symptomatic relief of pain, burning, urgency, frequency, and other discomforts arising from irritation of the lower urinary tract mucosa caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters.
Claims (2)
1 . A method for treatment of interstitial cystitis or painful bladder syndrome which method comprises administering a therapeutically effective amount of compound IV:
or a pharmaceutically acceptable salt or solvate thereof.
Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 14, 2025
From: KASHIV BIOSCIENCES, LLC
To: SHIVANKA RESEARCH, LLC
Reel/Frame 071115/0589 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 14, 2025
From: SHIVANKA RESEARCH, LLC
To: AMNEAL PHARMACEUTICALS LLC
Reel/Frame 071115/0600 →
SHORT FORM TERM LOAN INTELLECTUAL PROPERTY ASSIGNMENT
Recorded May 1, 2025
From: KASHIV BIOSCIENCES, LLC
To: ACQUIOM AGENCY SERVICES LLC, AS COLLATERAL AGENT
Reel/Frame 071150/0372 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 15, 2022
From: BRAHMKSHATRIYA, PATHIK SUBHASHCHANDRA; UNADKAT, VISHAL BHARATBHAI; GOSWAMI, VISHALGIRI GUNVANTGIRI; PANDYA, HETA NISHIL; MEHTA, SANDIP PARESHBHAI
To: KASHIV BIOSCIENCES, LLC
Reel/Frame 060449/0456 →
Priority Claims (1)
IN 201921034555
· Aug 27, 2019
· national
Continuity (1)
References Cited (17)
US 20040214753A1
· Britten et al.
· 2004
[cited by applicant]
US 20070208134A1
· Hunter et al.
· 2007
[cited by applicant]
US 20140128399A1
· Abraham et al.
· 2014
[cited by applicant]
CN 108635335A
· 2018
[cited by applicant]
J. G. Cannon, Chapter Nineteen in Burger's Medicinal Chemistry and Drug Discovery, Fifth Edition, vol. I: Principles and Practice, Wiley-Interscience 1995, pp. 783-802. (Year: 1995).
[cited by examiner]
Gaines, Kaye K. “Phenazopyridine Hydrochloride: The Use and Abuse of an Old Standby for UTI”. Medication Minute, 24(3):207-209 (2004).
[cited by applicant]
Shreve et al., “Studies in Azo Dyes. I. Preparation and Bacteriostatic Properties of Azo Derivatives of 2,6-Diaminopyridine,” Journal of the American Chemical Society, 65:2241-2243 (1943).
[cited by applicant]
Extended European Search Report mailed Aug. 16, 2023 for corresponding European Patent Application Serial No. 20858967.1.
[cited by applicant]
Tay and Grundy, “Animal Models of Interstitial Cystitis/Bladder Pain Syndrome,” Frontier in Physiology, 14:1-29 (2023).
[cited by applicant]
Auge et al., “Relevance of the Cyclophosphamide-Induced Cystitis Model for Pharmacological Studies Targeting Inflammation and Pain of the Bladder,” European Journal of Pharmacology, 707:32-40 (2013).
[cited by applicant]
Saban, “Angiogenic Factors, Bladder Neuroplasticity and Interstitial Cystitis—New Pathological Insights,” Transl Androl Urol, 4(5):555-562 (2015).
[cited by applicant]
Gousse et al., “Assessment of Bladder Pressure and Discomfort Symptoms: How do Overactive Bladder Differ from Interstitial Cystitis/Bladder Pain Syndrome Patients?” BMC Urology, 23(53):1-7 (2023).
[cited by applicant]
International Search Report dated Apr. 1, 2021, for corresponding International Patent Application No. PCT/IS20/58010.
[cited by applicant]
Written Opinion dated Apr. 1, 2021, for corresponding International Patent Application No. PCT/IS20/58010.
[cited by applicant]
Aizawa, et al.; “Effects of Phenazopyridine on Rat Bladder Primary Afferent Activity, and Comparison with Lidocaine and Acetaminophen”; Neurourology and Urodynamics, vol. 29(8):1445-50, (2010).
[cited by applicant]
Thomas et al.; “Excretion of Phenazopyridine and Its Metabolites in the Urine of Humans, Rats, A Mice, and Guinea Pigs”; Journal of Pharmaceutical Sciences, vol. 79(4), Apr. 1990.
[cited by applicant]